Trial Profile
Multicenter Retrospective Cohort Study Evaluating the Safety and Efficacy of TAS-102 in Patients with Metastatic Colorectal Cancer; the HGCSG1503 Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jul 2018
Price :
$35
*
At a glance
- Drugs Tipiracil/trifluridine (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 16 Jul 2018 Status changed from active, no longer recruiting to completed.
- 20 Jan 2018 Results assessing (n=411) the impact of primary tumor location in mCRC treated TAS-102 in the real-world clinical practice presented at the 2018 Gastrointestinal Cancers Symposium
- 20 Jan 2018 Results (n=126) comparing efficacy of TAS-102 after administration of regorafenib in the real world practice and other pivotal clinical trials, presented at the 2018 Gastrointestinal Cancers Symposium.